TerminatedPhase 2NCT04303845
Erenumab For Treatment of Hemicrania Continua
Studying Hemicrania continua
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Rashmi Halker Singh, MD, M.DMayo Clinic
- Intervention
- Erenumab(drug)
- Enrollment
- 2 enrolled
- Eligibility
- 18-66 years · All sexes
- Timeline
- 2021 – 2022
Study locations (1)
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04303845 on ClinicalTrials.govOther trials for Hemicrania continua
Additional recruiting or active studies for the same condition.